Recommendations for Successful Training on Methods of Delivery of Biologics for Cardiac Regeneration. A Report of the International Society for Cardiovascular Translational Research

Nabil Dib, Philippe Menasche, Jozef J. Bartunek, Andreas M. Zeiher, Andre Terzic, Nicolas A. Chronos, Timothy D. Henry, Nicholas S. Peters, Francisco Fernández-Avilés, Magdi Yacoub, Timothy A. Sanborn, Anthony DeMaria, Richard A. Schatz, Doris A. Taylor, Shmuel Fuchs, Silviu Itescu, Leslie W. Miller, Jonathan H. Dinsmore, George D. Dangas, Jeffrey J. PopmaJennifer L. Hall, David R. Holmes

Research output: Contribution to journalReview articlepeer-review

64 Scopus citations

Abstract

The field of myocardial regeneration (angiogenesis and myogenesis) might prove to play an important role in the future management of cardiovascular disease. Stem cells are currently undergoing testing in Phase I and Phase II clinical trials. Methods of delivery will affect the outcome of such therapies, perhaps significantly. This document provides suggested guidance in 4 methods of delivery: endocardial, intracoronary, coronary sinus, and epicardial.

Original languageEnglish (US)
Pages (from-to)265-275
Number of pages11
JournalJACC: Cardiovascular Interventions
Volume3
Issue number3
DOIs
StatePublished - Mar 2010

Bibliographical note

Funding Information:
Dr. Dib has received research grants from Cardiovascular Biotherapeutics and Angioblast Systems, Inc. ; and consultant fees from Biologics Delivery Systems, Inc. (Cordis Corporation), and Cardio3 Biosciences. Dr. Bartunek has received research grants from Cardio3 Biosciences . Dr. Zeiher is an advisor and co-founder of t2Cure. Dr. Peters has received research grants from CardioPolymers Inc. and Medtronic, Inc. ; is a consultant and honorarium recipient from CardioPolymers Inc., Ablation Frontiers Inc., AstraZeneca Inc., Sanofi Aventis Inc., Magnetecs Inc., Bard Inc., and Bioheart Inc.; and has intellectual property and stock in CardioPolymers Inc. Dr. Sanborn is on the Speakers' Bureau of Merck; and is a Chairman and on the Data Safety Monitoring Board of St. Jude Medical. Dr. DeMaria has received research grants from Lantheus , Acusphere , CV Therapeutics , Cardiovascular Biotherapeutics , Angioblast Systems, Inc. , Philips Medical Systems , and General Electric Medical Systems ; and has stock options in Cardionet. Dr. Schatz has a licensing agreement with Biologics Delivery Systems and Cordis Corporation; is on the Scientific Advisory Board and Data Safety Monitoring Board of Baxter; and is a Speaker for Cordis Corporation and Medtronic, Inc. Dr. Itescu is President and founder of Angioblast Systems, Inc. Dr. Miller has received a research grant from Thoratec Corp . Dr. Dangas is a consultant for and has received honoraria from Cordis Corporation; and is a speaker for Cordis Corporation, Medtronic, Inc, and Boston Scientific. Dr. Popma has received research grants from Abbott Vascular , Boston Scientific , Cordis , ev3 , and Medtronic, Inc. Dr. Hall is a consultant for Catholic Healthcare West; and has received grants NIH - R01HL081715A1 and NIH - 1R21DK078029-01 .

Keywords

  • catheter
  • injection
  • myocardial regeneration
  • stem cells
  • training

Fingerprint

Dive into the research topics of 'Recommendations for Successful Training on Methods of Delivery of Biologics for Cardiac Regeneration. A Report of the International Society for Cardiovascular Translational Research'. Together they form a unique fingerprint.

Cite this